SENTI BIOSCIENCES, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2787 USD | -0.78% |
|
-9.37% | -57.77% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 290.5 | 61.84 | 29.4 |
| Enterprise Value (EV) 1 | 256.1 | -1.052 | 31.1 |
| P/E ratio | -2.65 x | -0.63 x | -0.41 x |
| Yield | - | - | - |
| Capitalization / Revenue | 105 x | 14.4 x | 11.5 x |
| EV / Revenue | 92.7 x | -0.25 x | 12.1 x |
| EV / EBITDA | -6.45 x | 0.02 x | -0.51 x |
| EV / FCF | -14,290,608 x | 17,088 x | -413,869 x |
| FCF Yield | -0% | 0.01% | -0% |
| Price to Book | -1.34 x | 0.49 x | 0.45 x |
| Nbr of stocks (in thousands) | 29,466 | 43,857 | 44,545 |
| Reference price 2 | 9.860 | 1.410 | 0.6600 |
| Announcement Date | 01/04/22 | 22/03/23 | 21/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 0.085 | 0.566 | 2.761 | 4.286 | 2.561 |
| EBITDA 1 | -21.36 | -24.13 | -39.68 | -69.23 | -60.88 |
| EBIT 1 | -21.78 | -24.69 | -40.45 | -70.63 | -64.44 |
| Operating Margin | -25,625.88% | -4,362.9% | -1,464.9% | -1,647.9% | -2,516.28% |
| Earnings before Tax (EBT) 1 | -21.16 | -19.86 | -55.32 | -58.21 | -83.41 |
| Net income 1 | -21.16 | -19.86 | -55.32 | -58.21 | -71.06 |
| Net margin | -24,890.59% | -3,509.19% | -2,003.59% | -1,358.14% | -2,774.62% |
| EPS 2 | -1.557 | -1.433 | -3.717 | -2.229 | -1.601 |
| Free Cash Flow | - | -14.3 | -17.92 | -61.54 | -75.14 |
| FCF margin | - | -2,526.28% | -648.99% | -1,435.75% | -2,933.98% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 14/02/22 | 14/02/22 | 01/04/22 | 22/03/23 | 21/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|
| Net sales 1 | 1.766 | 0.059 | 1.286 | 0.937 | 0.338 |
| EBITDA | - | -19.57 | - | - | - |
| EBIT 1 | -17.08 | -20.02 | -19.83 | -19.64 | -18.18 |
| Operating Margin | -967.44% | -33,925.42% | -1,542.3% | -2,095.52% | -5,380.18% |
| Earnings before Tax (EBT) 1 | - | -18.21 | -18.72 | -18.7 | -36.62 |
| Net income 1 | -16.64 | -18.21 | -18.72 | -18.7 | -36.62 |
| Net margin | -942.24% | -30,864.41% | -1,455.83% | -1,995.41% | -10,832.84% |
| EPS 2 | -0.3800 | -0.4200 | -0.4200 | -0.4200 | -0.3400 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 10/11/22 | 22/03/23 | 09/05/23 | 11/08/23 | 14/11/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 1.7 |
| Net Cash position 1 | 3.02 | 16.5 | 34.5 | 62.9 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.0279 x |
| Free Cash Flow | - | -14.3 | -17.9 | -61.5 | -75.1 |
| ROE (net income / shareholders' equity) | - | -81.2% | -121% | -62% | -85.9% |
| ROA (Net income/ Total Assets) | - | -36.7% | -34.9% | -31.8% | -26.8% |
| Assets 1 | - | 54.17 | 158.7 | 183 | 264.9 |
| Book Value Per Share 2 | -2.900 | -4.050 | -7.340 | 2.890 | 1.460 |
| Cash Flow per Share 2 | 0.3900 | 2.110 | 3.690 | 1.310 | 0.7900 |
| Capex 1 | 2 | 1.16 | 5.54 | 41.4 | 12 |
| Capex / Sales | 2,348.24% | 205.12% | 200.76% | 965.33% | 470.05% |
| Announcement Date | 14/02/22 | 14/02/22 | 01/04/22 | 22/03/23 | 21/03/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -57.77% | 13.27M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SNTI Stock
- Financials Senti Biosciences, Inc.
